These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33286319)

  • 1. Pricing Constraint and the Complexity of IPO Timing in the Stock Market: A Dynamic Game Analysis.
    Hu Z; Hu Y; Jiang Y; Peng Z
    Entropy (Basel); 2020 May; 22(5):. PubMed ID: 33286319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Empirical Study on the Relationship between Stock Price Information and Enterprise Innovation Management Based on Information Learning Mechanism.
    Bai M
    Comput Intell Neurosci; 2022; 2022():9425405. PubMed ID: 35619758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does media sentiment affect stock prices? Evidence from China's STAR market.
    Dong X; Xu S; Liu J; Tsai FS
    Front Psychol; 2022; 13():1040171. PubMed ID: 36533006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Registration Reform and the Role of Political Connections in the Initial Public Offering Process: Evidence From China.
    Wu X; Zhou Q
    Front Psychol; 2022; 13():853644. PubMed ID: 35592153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Did the COVID-19 pandemic (really) positively impact the IPO Market? An Analysis of information uncertainty.
    Baig AS; Chen M
    Financ Res Lett; 2022 May; 46():102372. PubMed ID: 35431676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data of pre-IPO or listing firm characteristics and post-listing stock returns of Chinese listed firms.
    Li H
    Data Brief; 2020 Apr; 29():105226. PubMed ID: 32181288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of environmental information disclosure on stock price synchronicity in China.
    Yang Y; Zhang J; Li Y
    Heliyon; 2023 May; 9(5):e16271. PubMed ID: 37251833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Related to Small- and Mid-Capitalization Pharmaceutical Company Success Using Stock Performance as a Surrogate.
    Ferris MJ; Sun K; Savard C; Suresh T; Mishra MV
    Cureus; 2021 Sep; 13(9):e18210. PubMed ID: 34692353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to improve the function of government carbon tax in promoting enterprise carbon emission reduction: from the perspective of three-stage dynamic game.
    Qu X; Sun X
    Environ Sci Pollut Res Int; 2022 May; 29(21):31348-31362. PubMed ID: 35006566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable stocks, boundedly rational stock markets and IPO entry rates.
    Chok J; Qian J
    PLoS One; 2013; 8(5):e61474. PubMed ID: 23690924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in biopharmaceutical IPOS: 1996-2005.
    Williams DR; Young CC
    J Health Care Finance; 2006; 33(2):39-54. PubMed ID: 19175239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Environmental pollution and sustainability of IPO performance: evidence from the Pakistani Market.
    Mehmood W; Alsmady AA; Amin S; Mohd-Rashid R; Aman-Ullah A
    Environ Sci Pollut Res Int; 2023 Mar; 30(11):30073-30086. PubMed ID: 36427127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Psychological Expectation of New Project Income Under the Influence of the Entrepreneur's Sentiment From the Perspective of Information Asymmetry.
    Zhong H; Yan R; Li S; Chen M
    Front Psychol; 2020; 11():1416. PubMed ID: 32774311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the Relationship Between Entity Financialization, Managers' Incentives, and Enterprise's Innovation: Fresh Evidence From China.
    Xu C; Zhang H; Wang M; Iqbal A
    Front Psychol; 2021; 12():810294. PubMed ID: 35308072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unlocking the black box: Non-parametric option pricing before and during COVID-19.
    Gradojevic N; Kukolj D
    Ann Oper Res; 2022 Feb; ():1-24. PubMed ID: 35233127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competitive pricing of substitute products under supply disruption.
    Gupta V; Ivanov D; Choi TM
    Omega; 2021 Jun; 101():102279. PubMed ID: 32836689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. China's Jinshan Yinshan sustainability evolutionary game equilibrium research under government and enterprises resource constraint dilemma.
    Li C; Firdousi SF; Afzal A
    Environ Sci Pollut Res Int; 2022 Jun; 29(27):41012-41036. PubMed ID: 35083699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stock Market Liberalization and Corporate Green Innovation: Evidence from China.
    Zhang Y; Zhang J; Cheng Z
    Int J Environ Res Public Health; 2021 Mar; 18(7):. PubMed ID: 33806099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustainability reporting and corporate reputation of Malaysian IPO companies.
    Abbas YA; Mehmood W; Lazim YY; Aman-Ullah A
    Environ Sci Pollut Res Int; 2022 Nov; 29(52):78726-78738. PubMed ID: 35697988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asian rainbow option pricing formulas of uncertain stock model.
    Gao R; Wu W; Liu J
    Soft comput; 2021; 25(14):8849-8873. PubMed ID: 34121922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.